English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Chronic kidney disease mineral and bone disorder is a metabolic bone disease present in almost all uremic patients. There are no good markers of bone resorption available for uremic patients. The validity of parathormone as a surrogate marker of bone and mineral disorders has been questioned over the past decade. We need to shift from Surrogate markers to bone markers.

The need for a reliable bone biomarker to better assess chronic kidney disease mineral and bone disorder